Please assess the completion status of the following clinical trial:

Trial Title: A Study of JNJ-53718678 in Participants With Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A woman of childbearing potential must have a negative serum (beta human chorionic gonadotropin \[beta-HCG\]) test at screening and on Day -1 of the treatment period~* Contraceptive use by female participants or women should be consistent with local regulations regarding the use of contraceptive methods for participant participating in clinical studies~* If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 30 days after receiving the study drug~* A male participant must agree not to donate sperm for the purpose of reproduction from Day -1 of the study and for a minimum of 90 days after receiving the study drug~* For participants with mild, moderate or severe hepatic impairment: the participants must have a total Child-Pugh score of 5 to 6, inclusive (mild); or 7 to 9, inclusive (moderate); or 10-15, inclusive (severe). The Investigator will determine degree of hepatic impairment~Exclusion Criteria:~* Known allergies, hypersensitivity, or intolerance to JNJ-53718678 or its excipients~* Donated blood or blood products or had substantial loss of blood (more than 500 milliliter \[mL\]) within 90 days before the administration of study drug or intention to donate blood or blood products during the study~* Received an experimental drug (including investigational vaccines) or used an experimental medical device within 30 days or within a period less than 5 times the drug's half-life, whichever is longer, before the dose of the study drug is scheduled~* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments~* Preplanned surgery or procedures that would interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: Participants with Mild Hepatic Impairment (Type: EXPERIMENTAL): Participants with mild hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
- Group 2: Participants with Moderate Hepatic Impairment (Type: EXPERIMENTAL): Participants with moderate hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
- Group 3: Participants with Severe Hepatic Impairment (Type: EXPERIMENTAL): Participants with severe hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
- Group 4: Participants with Normal Hepatic Function (Type: EXPERIMENTAL): Participants with normal hepatic function will receive a single oral dose of JNJ-53718678 suspension on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility